Ticker Launch
Sign inTry it free

Reverse merger · Completed · OBX

Obsidian Therapeutics, Inc.

Reverse merger with Galera Therapeutics, Inc. (GRTX)

Obsidian Therapeutics, Inc. merged into Galera Therapeutics, Inc. (GRTX), a clinical-stage biotech quoted on OTCQB after winding down its own programs, in a reverse merger that takes the private company public. The deal was announced on Apr 14, 2026 and closed on Aug 3, 2026. The combined company trades as Obsidian Therapeutics, Inc. (OBX) on Nasdaq.

Obsidian Therapeutics, Inc. is a clinical-stage biopharmaceutical company using protein-regulation technology to develop engineered tumor-infiltrating lymphocyte cell therapies for solid tumors. Its lead candidate OBX-115 is in Phase 2 for advanced melanoma and Phase 1 for NSCLC.

Status
Completed
Private company
Obsidian Therapeutics, Inc.
Public company
Galera Therapeutics, Inc. (GRTX)
Public company business before
clinical-stage biotech quoted on OTCQB after winding down its own programs
Announced
Apr 14, 2026
Closed
Aug 3, 2026
Combined company
Obsidian Therapeutics, Inc. (OBX)
Exchange
Nasdaq
Sector
Biotech & pharma

More on this deal for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other completed reverse mergers